Format

Send to

Choose Destination

See 1 citation in Drugs Context 2019:

Drugs Context. 2019 Mar 13;8:212566. doi: 10.7573/dic.212566. eCollection 2019.

Agents to treat BRAF-mutant lung cancer.

Author information

1
Division of Medical Oncology, Department of Internal Medicine, The James Cancer Center and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.

Abstract

BRAF mutations are seen in up to 3.5-4% of the non-small cell lung cancer (NSCLC) patients. BRAF V600E mutations account for 50% of these cases, and the remaining BRAF mutations are non-V600E. The biologic behavior of BRAF-mutated lung tumors tends to be more aggressive and resistant to chemotherapy, but responses to tyrosine kinase inhibitors such as BRAF inhibitors with or without MEK inhibitors have provided another effective tool to attain better response rates when compared to cytotoxic chemotherapy. New strategies such as immunotherapy are becoming as well another option to treat in the second-line setting patients with BRAF-mutated NSCLC.

KEYWORDS:

dabrafenib; immunotherapy; lung neoplasm; proto-oncogene protein B-raf; trametinib

Conflict of interest statement

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at http://www.drugsincontext.com/wp-content/uploads/2019/01/dic.212566-COI.pdf

Publication type

Publication type

Supplemental Content

Full text links

Icon for Just Medical Media Limited Icon for PubMed Central
Loading ...
Support Center